Home Featured Page 264

Featured

Latest

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

PTSF64 – The First Woman to Take Acid, The Drug Policy...

atai Life Sciences Announces Pricing of Upsized Initial Public Offering

Diamond Therapeutics contracts BioPharma Services for Phase 1 clinical trial

Revive Collaborates With University of Health Sciences Antigua To Pioneer Clinical...

Silo Wellness and Entheon Biomedical’s Wholly-Owned Subsidiary, HaluGen Life Sciences, Announces...

Awakn Life Sciences Corp. Announces Completion Of Reverse Takeover Transaction, Release...

Algernon Pharmaceuticals Targets First Human Study of its Psychedelic Drug DMT...

MYND Life Sciences Announces LOI with Eyam Vaccines and Immunotherapeutics

Psyence Group Announces Collaboration with the Scientific Research Council (SRC) of...

MindMed Appoints Pharmaceutical Veteran Peter Bergethon, M.D. to Scientific Advisory Board

EDITOR PICKS

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

The Best Psychedelic Education Does Not Look Psychedelic

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

PTSF64 – The First Woman to Take Acid, The Drug Policy...

atai Life Sciences Announces Pricing of Upsized Initial Public Offering

Diamond Therapeutics contracts BioPharma Services for Phase 1 clinical trial

Revive Collaborates With University of Health Sciences Antigua To Pioneer Clinical...

Silo Wellness and Entheon Biomedical’s Wholly-Owned Subsidiary, HaluGen Life Sciences, Announces...

Awakn Life Sciences Corp. Announces Completion Of Reverse Takeover Transaction, Release...

Algernon Pharmaceuticals Targets First Human Study of its Psychedelic Drug DMT...

MYND Life Sciences Announces LOI with Eyam Vaccines and Immunotherapeutics

Psyence Group Announces Collaboration with the Scientific Research Council (SRC) of...

MindMed Appoints Pharmaceutical Veteran Peter Bergethon, M.D. to Scientific Advisory Board

EDITOR PICKS

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY